CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2024-- 2seventy bio, Inc . (Nasdaq: TSVT), announced today that members of the management team will present at the following upcoming investor conferences: Guggenheim Healthcare Talks 6 th Annual Biotechnology Conference , the St.
PRINCETON, N.J. , & CAMBRIDGE, Mass. --(BUSINESS WIRE)--Feb. 5, 2024-- Bristol Myers Squibb (NYSE: BMY) and 2seventy bio, Inc. (Nasdaq: TSVT) today announced that a notice was published in the Federal Register that the U.S. Food and Drug Administration (FDA) will convene a virtual meeting of the
- Company to focus exclusively on commercialization and development of Abecma , in partnership with Bristol Myers Squibb - - Company to sell R&D pipeline to Regeneron to launch Regeneron Cell Medicines business led by 2seventy bio’s Chief Scientific Officer, Philip Gregory - Chip Baird named